Veterans and Lawmakers Lobby in Bipartisan Push for MDMA Therapy

The Food and Drug Administration (FDA) is close to making a decision on a potential treatment for post-traumatic stress disorder (PTSD) that combines talk therapy with MDMA, known as Ecstasy or Molly. The decision, expected soon, has led to increased lobbying from veterans groups, researchers, and members of Congress. A letter signed by 80 lawmakers urged the FDA to approve the application by pharmaceutical company Lykos Therapeutics. This push follows the rejection of Lykos’s application in June due to flaws in clinical trials and insufficient data. The campaign aims to address the mental health crisis and high suicide rates among veterans.